6505--Mycophenolate Mofetil RFI

Closed Pre-Solicitation Posted

Solicitation number
36E79725Q0002
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs National Acquisition Center is conducting market research to establish a national mandatory requirements contract for Mycophenolate Mofetil capsules and tablets. This procurement will serve the VA, Department of Defense, Indian Health Service, Bureau of Prisons, and Federal Health Care Center. Key requirements include offerors providing unique 11-digit National Drug Codes, having a letter of commitment from the manufacturer if not the manufacturer, and having agreements with the Pharmaceutical Prime Vendors. The agency is seeking U.S. end-made or designated end-made products and intends to award at prices lower than FSS/open market based on the committed purchase volume across the agencies. Responses to the market research questionnaire are due by November 19, 2024 at 2:30 pm CT.

This procurement is not set-aside and the agency has not named any potential incumbents or current contractors. The total estimated annual usage across the four Mycophenolate Mofetil product descriptions ranges from 7,307 to 18,706 bottles. The resultant contract will have a base year with up to four one-year option periods.

Notice text

MARKET RESEARCH QUESTIONNAIRE

Company Name: _________________________

I am conducting market research for the procurement of Mycophenolate Mofetil capsules and tablets for the Department of Veterans Affairs (VA), Department of Defense (DOD), Indian Health Service (IHS), Bureau of Prisons (BOP), and Federal Health Care Center (FHCC). This procurement will result in a national mandatory requirements contract for the above agencies. Other companies with the same/similar product will be blocked out for ordering; therefore it is our goal to award lower than FSS/Open Market prices on the resultant national contract based on purchases of a committed volume. These products will be awarded in the aggregate for all strengths and sizes for the base year and all option years included in the solicitation. Please provide a response to the following:

1. Is your Company able to meet the following minimum requirements:

National Drug Code: Offerors shall provide a separate and distinct eleven-digit National Drug Code (NDC) number unique to the offeror (e.g., 00012-3456-78) for each product proposed. The first five numbers of the eleven-digit NDC number for each product proposed shall identify the offeror. Does your company have a unique NDC (Labeler Code)?_____________

If the offeror is not the manufacturer of the offered items, the offeror shall submit a letter of commitment from the manufacturer to the offeror which will assure the offeror a source of supply sufficient to satisfy the Government's requirements for the contract period. Name of Manufacturer:_________________

Is the Manufacturer a Large or Small business (using the SBA size standards for NAICS code 325412? ____________________

Would you be able to provide a letter of commitment from the manufacturer of the offered drug?_____________

Pharmaceutical Prime Vendor: All Ordering Activities under the Department of Veterans Affairs and Department of Defense acquire their pharmaceutical requirements through their Pharmaceutical Prime Vendor Program (PPV). The contractor shall ensure that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders, if an award is made. Does your company currently have a business-to-business agreement with the PPVs?_________

d. Under NAICS code 325412, is your company size (check one):

Large Business ______

Small Business ______

e. If a small business, does your company manufacture (measure, weigh, mix, and compound) at least 50% of the product offered?_________

f. Is the offered end product U.S end-made or designated end made product?_________

g. Can your company meet the following product, bottle size and usage:

ITEM

DESCRIPTION

PACKAGE SIZE (Capsules/Tablets per Bottle)

TOTAL ESTIMATED ANNUAL USAGE (Bottles)

1

MYCOPHENOLATE MOFETIL 250MG CAP

100

18,706

2

MYCOPHENOLATE MOFETIL 250MG CAP

500

17,378

3

MYCOPHENOLATE MOFETIL 500MG TAB

100

7,307

4

MYCOPHENOLATE MOFETIL 500MG TAB

500

18,281

2 . Is your Company interested in submitting a response to a solicitation?________

3. As this is a national standardized contract, our preference is for a base plus four option years to provide our customers continuity and consistency of product by allowing long term committed purchases of your product. If interested, please indicate Base year and how many Option periods, not to exceed 4._________________

4. If an award were to be made based on the above requirements, would your company be able to begin supplying the product in the estimated quantities within 60 days of the contract award date?

______________________________________________________________________

5. If your company is not interested in participating, please respond with the reason why. This aids our market research for future procurements.

______________________________________________________________________

Please provide your responses as soon as possible. Please contact Amber Zavala for any questions. Amber.Zavala@va.gov.

Files

File Type Posted
36E79725Q0002.docx DOCX document

Similar open opportunities

Opportunity Agency Set-aside Responses due
6505--Imatinib Tablets NAICS 325412 National Acquisition Center No set-aside
6505--Sodium Bicarbonate Injection Vial Restricted to Made in America NAICS 325412 National Acquisition Center No set-aside
Methylphenidate ER NAICS 325412 Medical Supply Chain No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity